
Ascletis says oral acne drug shows "exceptional efficacy"
Hong Kong biotech Ascletis is planning to file a new oral treatment for acne for approval in China soon, on the back of new phase 3 data that suggests it could be a big step forward in treatment for the skin disorder. Denifanstat (ASC40) – vying to become …